Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB
Top Cited Papers
- 1 February 2002
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 20 (2) , 143-148
- https://doi.org/10.1038/nbt0202-143
Abstract
The ex vivo priming and expansion of human cytotoxic T lymphocytes (CTLs) has potential for use in immunotherapy applications for cancer and infectious diseases. To overcome the difficulty in obtaining sufficient numbers of CTLs, we have developed artificial antigen-presenting cells (aAPCs) expressing ligands for the T-cell receptor (TCR) and the CD28 and 4-1BB co-stimulatory surface molecules. These aAPCs reproducibly activate and rapidly expand polyclonal or antigen-specific CD8+ T cells. The starting repertoire of CD8+ T cells was preserved during culture. Furthermore, apoptosis of cultured CD8+ T cells was diminished by this approach. This approach may have important therapeutic implications for adoptive immunotherapy.Keywords
This publication has 42 references indexed in Scilit:
- Response Differences between Human CD4+ and CD8+ T-Cells during CD28 Costimulation: Implications for Immune Cell-Based Therapies and Studies Related to the Expansion of Double-Positive T-Cells during AgingClinical Immunology, 2000
- Expression of Bcl-XL Restores Cell Survival, but Not Proliferation and Effector Differentiation, in Cd28-Deficient T LymphocytesThe Journal of Experimental Medicine, 2000
- Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathwayEuropean Journal of Immunology, 1998
- Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.Journal of Clinical Investigation, 1997
- B7‐1‐dependent co‐stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cellsEuropean Journal of Immunology, 1997
- Principles for Adoptive T Cell Therapy of Human Viral DiseasesAnnual Review of Immunology, 1995
- Molecular cloning of a ligand for the inducible T cell gene 4‐1BB: a member of an emerging family of cytokines with homology to tumor necrosis factorEuropean Journal of Immunology, 1993
- Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell ClonesScience, 1992
- Phase I Study of Cellular Adoptive Immunotherapy Using Genetically Modified CD8+ HIV-Specific T Cells for HIV Seropositive Patients Undergoing Allogeneic Bone Marrow Transplant. Fred Hutchinson Cancer Research Center and the University of WashingtonHuman Gene Therapy, 1992
- Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene TransductionNew England Journal of Medicine, 1990